Company Performance Metrics
- Joanne Beck: CTO
- Andrea van Elsas: Chief Scientific Officer
Abata Therapeutics is focused on translating the biology of regulatory t cells into transformational medicines for patients living with progressive multiple sclerosis and other severe autoimmune and inflammatory diseases. Abata leverages regulatory T cells (Tregs) to create therapies that aim to restore immune system balance in patients with
autoimmune conditions. The company's approach involves engineering Tregs to specifically target disease-related antigens, allowing for precise and effective treatment of diseases like multiple sclerosis (MS) and type 1 diabetes.
Abata Therapeutics was founded by industry experts with deep experience in immunology and cell therapy, and it has received significant investment from venture capital firms and biopharmaceutical companies. The company's goal is to translate cutting-edge science into therapies that can significantly improve the lives of patients suffering from chronic autoimmune diseases.
